TY - JOUR
T1 - Combined therapy with peritoneal dialysis and hemodialysis
T2 - A multicenter retrospective observational cohort study in Japan
AU - Maruyama, Yukio
AU - Yokoyama, Keitaro
AU - Nakayama, Masaaki
AU - Higuchi, Chieko
AU - Sanaka, Tsutomu
AU - Tanaka, Yoshihide
AU - Sakai, Ken
AU - Mizuiri, Sonoo
AU - Otsuka, Yasushi
AU - Kuriyama, Satoru
AU - Maeba, Teruhiko
AU - Iwasawa, Hideaki
AU - Nakao, Toshiyuki
AU - Hosoya, Tatsuo
N1 - Publisher Copyright:
© 2014 S. Karger AG, Basel.
PY - 2014/5/22
Y1 - 2014/5/22
N2 - Background/Aims: Combining peritoneal dialysis (PD) and hemodialysis (HD) has been common treatment option in Japan. Methods: In this retrospective, multicenter, observational study, the clinical characteristics and outcomes of 104 patients (57 ± 11 years, males 72%) who had switched from PD alone to combined therapy with PD and HD were studied. Clinical parameters were measured at baseline and after 3 months of combined therapy. Results: At baseline, urine volume, dialysate-to-plasma ratio of creatinine (D/P Cr), and total Kt/V were 150 ml/day (range: 0-2,000 ml/day), 0.67 ± 0.11, and 1.8 ± 0.4, respectively. During the first 3 months of combined therapy, body weight, urine volume, serum creatinine level, and D/P Cr decreased, whereas hemoglobin levels increased. Conclusions: In patients where PD does not result in acceptable outcomes, combined therapy with PD and HD may have potential benefits in terms of dialysis adequacy and hydration status.
AB - Background/Aims: Combining peritoneal dialysis (PD) and hemodialysis (HD) has been common treatment option in Japan. Methods: In this retrospective, multicenter, observational study, the clinical characteristics and outcomes of 104 patients (57 ± 11 years, males 72%) who had switched from PD alone to combined therapy with PD and HD were studied. Clinical parameters were measured at baseline and after 3 months of combined therapy. Results: At baseline, urine volume, dialysate-to-plasma ratio of creatinine (D/P Cr), and total Kt/V were 150 ml/day (range: 0-2,000 ml/day), 0.67 ± 0.11, and 1.8 ± 0.4, respectively. During the first 3 months of combined therapy, body weight, urine volume, serum creatinine level, and D/P Cr decreased, whereas hemoglobin levels increased. Conclusions: In patients where PD does not result in acceptable outcomes, combined therapy with PD and HD may have potential benefits in terms of dialysis adequacy and hydration status.
KW - Dialysate-to-plasma ratio of creatinine (D/P Cr)
KW - Dialysis adequacy
KW - Hemodialysis
KW - Peritoneal dialysis
KW - Peritoneal equilibration test (PET)
KW - Residual renal function
KW - β2 microglobulin
UR - http://www.scopus.com/inward/record.url?scp=84917729683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84917729683&partnerID=8YFLogxK
U2 - 10.1159/000368389
DO - 10.1159/000368389
M3 - Article
C2 - 25471451
AN - SCOPUS:84917729683
VL - 38
SP - 149
EP - 153
JO - Blood Purification
JF - Blood Purification
SN - 0253-5068
IS - 2
ER -